An interventional study of Smartphone-based Mindfulness Exercise and Smartphone-based Psychoeducation in Psychosis, Anxiety and Depression, sponsored by Mclean Hospital. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by Mclean Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Psychotic Disorders by Mclean Hospital — 6 open to participants now, 6 under way, none of them phase 3. Psychotic Disorders · Mclean Hospital.
Among the 18 studies in Psychotic Disorders by Mclean Hospital, this one is the 15th largest by planned enrollment of the 17 interventional ones that give a count, is the only one that started in 2027, is one of 11 with no phase, and was the 18th registered.
1,593 studies on the registry are indexed under Psychotic Disorders; 283 are open to participants now.
Browse Psychotic Disorders studies →6 of the 18 studies in Psychotic Disorders by Mclean Hospital are open now, in 1 country. Recruiting first, the newest first:
Mclean Hospital · Sites in United States
Ages 18–55
Mclean Hospital · Sites in United States
Ages 18–45
Mclean Hospital · Sites in United States
Mclean Hospital · Sites in United States
Ages 18–55
Mclean Hospital · Sites in United States
Ages 18–45
By country, each count listing its studies:
Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10 is below the median of 65 across 1,326 interventional studies indexed under Psychotic Disorders.
Median enrollment 50 across the 17 interventional studies, 187 across the 1 observational. Of the 12 that completed or were terminated, 10 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
Mclean Hospital is the lead sponsor of 185 studies on the registry; 31 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 12 (80%) have results posted.
3 of the studies in Psychotic Disorders by Mclean Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07503093Mclean HospitalPilot Study of Sensor-Informed Smartphone-based Mental Health Interventions for Mood in Early Psychosis | 2027-05-01 |
| NCT06558201Mclean HospitalOpen Label Extension Study of NCT06221852 | 2027-09-30 |
| NCT06221852Mclean HospitalKetogenic and Nutritional Interventions for First Episode Bipolar Disorder | 2027-09-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 18 studies in Psychotic Disorders by Mclean Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of this trial is to evaluate the feasibility and preliminary efficacy of using passive smartphone sensors to detect moments of heightened negative mood and inform the timing of brief mental health interventions, such as mindfulness exercises and psychoeducation, in adults with early psychosis.
Negative mood symptoms are highly prevalent in early psychosis and strongly linked to long-term functional impairment and risk of relapse. Smartphone-based interventions offer a scalable and accessible solution for delivering personalized mental health support in daily life.
The goal of this micro randomized trial (MRT) is to evaluate the feasibility of using passive smartphone sensor data and machine learning to identify optimal moments for delivering smartphone app-based brief mental health interventions such as mindfulness exercises and psychoeducation, specifically moments when individuals are both most in need of support and most receptive to it.
The primary aim of this pilot study is to assess the feasibility and acceptability of the MRT study design, including recruitment and retention rates, EMA adherence, and participant feedback gathered through qualitative exit interviews to inform future design improvements. A secondary aim is to evaluate the feasibility of training an idiographic machine learning model using passive smartphone sensor data to detect moments of heightened negative affect. An exploratory aim is to estimate preliminary intervention effect sizes to inform a future fully powered clinical trial and to identify contextual factors associated with participant engagement.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Each participant is randomized four times per day to receive one of four conditions with equal probability (33.3% each): a mindfulness exercise, psychoeducation, a neutral control message. A brief EMA is completed before and after each randomization event to measure proximal changes in mood (sadness, anxiety, irritability, stress, rumination).
Behavioral: Smartphone-based Mindfulness Exercise · Behavioral: Smartphone-based Psychoeducation · Behavioral: Neutral Control Message
A brief approximately 1 minute video guided mindfulness based breathing exercise designed to anchor attention to the present moment and reduce negative affect in the moment by guiding participants through a structured breathing technique.
A brief text or video based psychoeducation message delivered via the smartphone app. Content covers the nature of emotions and emotion regulation strategies, aimed at improving emotional awareness and coping skills in the moment.
A brief text or video based message containing random facts delivered via the MetricWire smartphone app. This serves as an active control condition to allow comparison with the active intervention conditions.
Retention Rate
Proportion of enrolled participants who completed the full 10 week study protocol, including both Phase 1 and Phase 2.
Time frame: 10 weeks
EMA Completion Rate
Proportion of ecological momentary assessment (EMA) prompts answered by participants out of the total number delivered during Phase 1 and Phase 2.
Time frame: 10 weeks
Participant Acceptability and Satisfaction
Participant acceptability and satisfaction with the study app and intervention content, assessed through a structured qualitative exit interview and feedback questionnaire at the end of the study.
Time frame: Week 10
Proximal Change in Negative Affect
Change in self reported negative affect from pre to post intervention phone-based ecological momentary assessment at each randomization event during the micro-randomized trial. Negative affect is assessed using a visual analog scale (0 to 100) measuring sadness, anxiousness, irritability, and rumination. Active intervention conditions (mindfulness and psychoeducation) are compared to neutral control conditions to generate preliminary effect size estimates.
Time frame: 4 weeks
Patient Health Questionnaire-8 (PHQ-8)
All participants complete the Patient Health Questionnaire-8 (PHQ-8), an 8-item self-report measure of depressive symptom severity, at the start and at the end of the study. Each item is rated on a scale of 0 (not at all) to 3 (nearly every day), with total scores ranging from 0 to 24. Higher scores indicate greater depressive symptom burden.
Time frame: 4 weeks
Generalized Anxiety Disorder-7 (GAD-7)
All participants complete the Generalized Anxiety Disorder-7 (GAD-7), a 7-item self-report measure of anxiety symptom severity, at the start and at the end of the study. Each item is rated on a scale of 0 (not at all) to 3 (nearly every day), with total scores ranging from 0 to 21. Higher scores indicate greater anxiety symptom burdens.
Time frame: 4 weeks
Plan to share: No — This is a small pilot feasibility study with a sample size of 10 participants. Individual participant data will not be shared given the limited sample size, the exploratory and preliminary nature of the study, and the sensitive nature of the data collected. In particular, the study collects passive smartphone sensor data including GPS location data, which is inherently poses potential privacy risks. Findings from this pilot will inform the design of a future fully powered trial, at which point a formal data sharing plan will be developed.
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for May 2027, 3 months later.
Of 460 non-industry interventional studies with no phase under Psychotic Disorders, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 52. This study's planned 3 months is below that.
Counting every sponsor, half of 462 studies reached it within 34 months; a quarter within 19 and three quarters within 52.
Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Jan 2027, on Oct 5, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.